PercuSense
Curated by SignalMinimally invasive devices for continuous monitoring of glucose, sepsis, and cancer
Overview
Minimally invasive devices for continuous monitoring of glucose, sepsis, and cancer. The devices use physiological triggers to continuously monitor and diagnose the progression of diseases such as sepsis, cancer, or diabetes, aiming to provide an efficient and smart therapy. The products are claimed to be using a patent-pending calibration-free electrochemical sensor that combines principles of glucose detection inspired by islet cell technology with a sensing electrode design that yields a low-profile implant and superior mechanical stability. The products have trademarks such as Glycemico (glucose monitor) and Sirsdx (sepsis diagnosis and treatment).
Key facts
- Founded
- 2016
- Headquarters
- Santa Clarita, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 5 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view